Themis Medicare Ltd

Themis Medicare, a small-cap pharmaceutical company, reached a new 52-week low today amid a downward trend over the past eight days. Despite this, the stock outperformed its sector slightly. It experienced significant intraday volatility, trading below all major moving averages and showing a notable decline over the past year.

Themis Medicare has faced significant challenges, experiencing a 9.88% decline on February 18, 2025, and reaching a new 52-week low. The stock has seen consecutive losses over the past eight days, totaling 31.34%, and has underperformed its sector amid heightened volatility and a sustained downward trend.

Themis Medicare has faced significant volatility, hitting a new 52-week low and experiencing consecutive losses over the past eight days. The stock is currently trading below multiple moving averages and has declined 30.33% over the past year, contrasting with the overall market's positive performance.

Themis Medicare, a small-cap pharmaceutical company, is facing significant market challenges, trading near its 52-week low. The stock has declined 22.51% over the past week and 23.57% in the last year, underperforming its sector and remaining below key moving averages, indicating a sustained downward trend.

Themis Medicare recently reported its financial results for the quarter ending December 2024, revealing a significant reduction in its Debt-Equity Ratio. However, the company faces challenges, including a notable decline in Profit Before Tax, Profit After Tax, and Net Sales, alongside increased interest expenses and reduced cash reserves.

Themis Medicare, a small-cap pharmaceutical company, has faced a notable decline, losing 20.89% over the past six days. The stock is trading below multiple moving averages and is near its 52-week low. Recent trading has been marked by high volatility, with a monthly decline of 25.60%.

Themis Medicare, a small-cap pharmaceutical company, has recently experienced an evaluation adjustment amid flat financial performance for Q2 FY24-25. Key metrics reveal challenges in operational efficiency, modest sales growth, and potential liquidity issues, raising concerns about its long-term growth prospects and overall market sentiment.

Themis Medicare has faced significant challenges, experiencing an 8.23% decline on January 27, 2025, and a total drop of 14.45% over the past five days. The stock is trading below key moving averages, indicating a bearish trend, and has underperformed compared to the broader market indices.

Themis Medicare, a smallcap pharmaceutical company, has hit a 52-week high on November 18, 2024. With a 'Hold' rating from MarketsMOJO, the stock has gained 8.84% and outperformed the sector by 5.98%. It has also shown consecutive gains in the past two days and is trading above its moving averages, indicating a positive trend. Compared to the Sensex, Themis Medicare has a strong 1-year return of 86.28%, showcasing its growth potential in the pharmaceutical industry.

Themis Medicare, a smallcap pharmaceutical company, has seen a significant increase in its share price, reaching an all-time high on November 18, 2024. The stock has outperformed the sector by 8.95% and has been consistently trading above its moving averages. With a 88.07% growth in the past year, the company shows strong potential for growth in the pharmaceutical industry.

Themis Medicare, a smallcap pharmaceutical company, has reported a flat performance in the quarter ended September 2024, with a 'Hold' rating from MarketsMOJO. However, the company has shown a 32.06% YoY growth in PAT for the half-yearly period, indicating a positive trend. Its focus on innovation and quality has helped maintain a stable financial position.

Themis Medicare, a smallcap pharmaceutical company, has reached a new milestone as its stock price hit a 52-week high of Rs.304.3 on September 26, 2024. According to financial analysis platform MarketsMOJO, the stock call for Themis Medicare is 'Hold', indicating its strong performance in the market. The company has outperformed the sector and Sensex in the past year, showcasing its potential for growth in the pharmaceutical industry.

Themis Medicare, a smallcap pharmaceutical company, has reached an all-time high stock price of Rs.300.45 on September 26, 2024. It has been performing well in the market, with consecutive gains and trading above its moving averages. The company has shown a remarkable growth of 71.70% in the past year, outperforming the Sensex.

Themis Medicare, a smallcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on September 25th, 2024. The stock has been given a 'Hold' rating by MarketsMOJO and has outperformed the sector by 6.81%. With a positive trend in its performance and a strong 64.76% increase in the past year, the company shows potential for growth in the pharmaceutical industry.

On September 25th, 2024, Themis Medicare, a smallcap pharmaceutical company, saw a 7.27% increase in its stock, reaching a new 52-week high of Rs. 291. This outperforms the sector by 6.56%, indicating a strong performance. According to MarketsMOJO, the stock call for Themis Medicare is 'Hold', suggesting investors to hold onto their current positions. The stock has also shown a trend reversal and is trading higher than its moving averages, further supporting its positive performance. In comparison to the overall market, Themis Medicare has outperformed the Sensex by a significant margin, showing strong potential in the pharmaceutical industry.

Themis Medicare, a smallcap pharmaceutical company, has reached an all-time high in its stock price on September 25th, 2024. According to MarketsMOJO, the current call for the stock is 'Hold', indicating strong performance but not the best time to buy or sell. The stock has outperformed its sector and shown a positive trend, making it a company to watch in the pharmaceutical industry.

Themis Medicare, a smallcap pharmaceutical company, has reached a new milestone as its stock price hit a 52-week high on September 20, 2024. According to MarketsMOJO, the current recommendation for the stock is 'Hold', based on its strong performance and market trends. The stock has outperformed its sector by 11.42% today and is trading higher than its moving averages, indicating a positive trend. With a 68.11% increase in its stock price in the past year, Themis Medicare shows potential for growth in the pharmaceutical industry.

Themis Medicare, a smallcap pharmaceutical company, has reached an all-time high in its stock price on September 20, 2024. It has outperformed the sector by 9.15% and is currently trading at a price 1.61% away from its 52-week high. The stock has shown a strong performance in the past year, showcasing its potential in the pharmaceutical industry.